Detalhe da pesquisa
1.
A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models.
Haematologica;
105(3): 741-753, 2020 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31248974
2.
Selective CXCR4+ Cancer Cell Targeting and Potent Antineoplastic Effect by a Nanostructured Version of Recombinant Ricin.
Small;
14(26): e1800665, 2018 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29845742
3.
Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo.
Sci Transl Med;
16(734): eadg7962, 2024 Feb 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38354229
4.
T22-PE24-H6 Nanotoxin Selectively Kills CXCR4-High Expressing AML Patient Cells In Vitro and Potently Blocks Dissemination In Vivo.
Pharmaceutics;
15(3)2023 Feb 22.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36986589
5.
Engineering non-antibody human proteins as efficient scaffolds for selective, receptor-targeted drug delivery.
J Control Release;
343: 277-287, 2022 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35051493
6.
Time-Prolonged Release of Tumor-Targeted Protein-MMAE Nanoconjugates from Implantable Hybrid Materials.
Pharmaceutics;
14(1)2022 Jan 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35057088
7.
A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4+ lymphoma cells without toxicity in immunocompromised and immunocompetent mice.
Biomed Pharmacother;
150: 112940, 2022 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35421785
8.
A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model.
Biomaterials;
280: 121258, 2022 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34847435
9.
Biparatopic Protein Nanoparticles for the Precision Therapy of CXCR4+ Cancers.
Cancers (Basel);
13(12)2021 Jun 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34208189
10.
Antineoplastic effect of a diphtheria toxin-based nanoparticle targeting acute myeloid leukemia cells overexpressing CXCR4.
J Control Release;
335: 117-129, 2021 07 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34004204
11.
Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4+ Diffuse Large B-Cell Lymphoma Cells.
Int J Nanomedicine;
16: 1869-1888, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33716502
12.
An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.
J Hematol Oncol;
13(1): 36, 2020 04 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32295630
13.
Selective delivery of T22-PE24-H6 to CXCR4+ diffuse large B-cell lymphoma cells leads to wide therapeutic index in a disseminated mouse model.
Theranostics;
10(12): 5169-5180, 2020.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32373205
14.
Fluorescent Dye Labeling Changes the Biodistribution of Tumor-Targeted Nanoparticles.
Pharmaceutics;
12(11)2020 Oct 22.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33105866
15.
Engineering Secretory Amyloids for Remote and Highly Selective Destruction of Metastatic Foci.
Adv Mater;
32(7): e1907348, 2020 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31879981
16.
Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia.
Cancers (Basel);
10(11)2018 Nov 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30428571
17.
CXCR7 expression in diffuse large B-cell lymphoma identifies a subgroup of CXCR4+ patients with good prognosis.
PLoS One;
13(6): e0198789, 2018.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29920526